Canaccord analyst Whitney Ijem lowered the firm’s price target on Tenaya Therapeutics to $18 from $19 and keeps a Buy rating on the shares. The firm said its Q4 report was uneventful but said the focus remains on the lead AAV program, TN-201, which is currently dosing patients in a Ph1b study with initial data expected 2H24.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TNYA:
- Tenaya Therapeutics’ Financial Tightrope: Balancing Development Costs with Cash Reserves
- Tenaya Therapeutics reports Q4 EPS (40c), consensus (44c)
- Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
- Tenaya announces publication of TN-401 gene therapy preclinical data
